Tyra Biosciences, Inc.

Listed Company

TYRACIK 0001863127NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-119.95M

Total Assets

$282.61M

Equity

$259.18M

Shares Out

53.87M

Op. Cash Flow

$-95.14M

Business

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision small-molecule medicines targeting FGFR biology for oncology and genetically defined conditions. It designs and advances product candidates including TYRA-300, TYRA-200 and TYRA-430, leveraging its proprietary SNÅP platform for rapid molecular design and preclinical characterization. Its operations are organized around discovery and clinical development programs in FGFR3, FGFR2 and FGF19/FGFR4 biology. The company conducts global multi-center clinical trials and plans commercialization efforts primarily through direct development and potential partnerships across major markets.

Summary from filing dated 2025-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	103	80	63	43	21
General and administrative	30	24	17	16	6
Total operating expenses	133	104	80	59	26
Loss from operations	−133	−104	−80	−59	−26
Interest and other income, net	13	18	11	—	—
Total other income	13	18	11	4	−6,000
Net loss	−120	−86	−69	−55	−26
Unrealized gain (loss) on marketable securities available-for-sale, net	−377,000	389,000	381,000	0	—
Comprehensive loss	−120	−86	−69	−55	—
Net loss per share, basic	−2.01	−1.51	−1.62	−1.32	−1.91
Net loss per share, diluted	−2.01	−1.51	−1.62	−1.32	−1.91
Weighted-average shares used to compute net loss per share - basic	60	57	43	42	14
Weighted-average shares used to compute net loss per share - diluted	60	57	43	42	14

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	77	92	58	251	302
Marketable securities	179	249	145	0	—
Prepaid expenses and other current assets	9	6	8	6	2
Total current assets	265	347	212	257	304
Restricted cash	1	1	1	1	243,000
Property and equipment, net	1	2	2	1	1
Right-of-use asset	6	6	7	2	1
Other long-term assets	9	7	5	4	312,000
Total assets	283	364	226	266	307
Accounts payable	1	590,000	5	1	599,000
Lease liabilities, current	472,000	412,000	280,000	140,000	202,000
Accrued expenses and other current liabilities	16	14	10	4	3
Total current liabilities	18	15	15	6	4
Lease liabilities, noncurrent	5	6	6	2	981,000
Other long-term liabilities	0	3,000	46,000	169,000	367,000
Total liabilities	23	20	22	8	5
Commitments and contingencies (Note 10)	—	—	—	—	—
Preferred stock, $0.0001 par value; 50,000,000 shares authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024.	0	0	0	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 53,706,357 and 50,754,262 shares issued at December 31, 2025 and December 31, 2024, respectively, and 53,706,357 and 50,749,945 shares outstanding at December 31, 2025 and December 31, 2024, respectively.	5,000	5,000	4,000	4,000	4,000
Additional paid-in capital	630	594	369	354	342
Accumulated other comprehensive income	393,000	770,000	381,000	0	—
Accumulated deficit	−371	−251	−165	−96	−40
Total stockholders' equity	259	343	204	258	302
Total liabilities and stockholders' equity	283	364	226	266	307

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	546,000	519,000	357,000	296,000	140,000
Stock-based compensation	28	23	14	11	3
Accretion on marketable securities, net	−2	−6	−1	0	—
Prepaid expenses and other assets	−5	−169,000	−3	−8	−2
Accounts payable, accrued expenses and other liabilities	3	−744,000	9	2	1
Right-of-use assets and lease liabilities, net	83,000	184,000	−186,000	34,000	135,000
Net cash used in operating activities	−95	−70	−50	−50	−24
Purchases of marketable securities	−101	−264	−144	0	—
Maturities of marketable securities	174	166	0	—	—
Purchases of property and equipment	−141,000	−664,000	−770,000	−559,000	−661,000
Net cash provided by (used in) investing activities	72	−98	−145	−559,000	−645,000
Proceeds from issuances of common stock under benefit plans	8	3	2	632,000	514,000
Proceeds from issuance of common stock and pre-funded warrants from Private Placement	0	200	0	—	—
Payments of issuance costs for common stock and pre-funded warrants from Private Placement	0	−420,000	0	—	—
Net cash provided by financing activities	8	202	2	632,000	311
Net cash increase (decrease) for the period	−15	34	−193	−50	287
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities	68,000	0	125,000	0	209,000
Vesting of options early exercised subject to repurchase	3,000	43,000	124,000	197,000	—
Receivable from exercise of stock options included in prepaid expenses and other current assets	241,000	0	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro